Browsing: Vedotin

Sonesitatug vedotin (Sone-Ve), an antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), significantly improved overall survival (OS) in patients with second-…

Sigvotatug vedotin, an investigational IB6-directed antibody drug conjugate, did not significantly improve overall survival (OS) vs docetaxel among patients with…

Perioperative treatment with durvalumab (Imfinzi) in combination with neoadjuvant enfortumab vedotin-ejfv (EV; Padcev) demonstrated statistically significant and clinically meaningful improvements…

The FDA has granted priority review to a supplemental biologics license application for enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) for…

Treatment with tisotumab vedotin-tftv (Tivdak) in combination with carboplatin and pembrolizumab (Keytruda), with or without bevacizumab (Avastin), demonstrated antitumor activity…

Over half of patients with cervical cancer who received prior radiation achieved disease control, with approximately one-third achieving an objective…

Findings from the phase 3 KEYNOTE-B15/EV-304 trial (NCT04700124) revealed significant improvements in event-free survival (EFS), overall survival (OS), and pathological…